Prebiotic and Probiotic Regulation of Bone Health: Role of the Intestine and its Microbiome

Laura McCabe 1,2 · Robert A. Britton 3 · Narayanan Parameswaran 1

Published online: 30 September 2015
© Springer Science+Business Media New York 2015

Abstract Recent advances in our understanding of how the intestinal microbiome contributes to health and disease have generated great interest in developing strategies for modulating the abundance of microbes and/or their activity to improve overall human health and prevent pathologies such as osteoporosis. Bone is an organ that the gut has long been known to regulate through absorption of calcium, the key bone mineral. However, it is clear that modulation of the gut and its microbiome can affect bone density and strength in a variety of animal models (zebrafish, rodents, chicken) and humans. This is demonstrated in studies ablating the microbiome through antibiotic treatment or using germ-free mouse conditions as well as in studies modulating the microbiome activity and composition through prebiotic and/or probiotic treatment. This review will discuss recent developments in this new and exciting area.

Keywords Bone density · Prebiotics · Probiotics · Microbiome · Osteoblast · Osteoclast

Introduction

Recent advances in how microbial communities inhabiting the human body contribute to health and disease have generated great enthusiasm for the use of microbes to improve human health. Although microbes colonize most of the human body, the intestinal microbiota is by far the largest consortia associated with humans and has received the lion’s share of attention in microbiome research. The association of altered microbial communities with diseases that are directly associated with the gut, such as obesity, diabetes, and inflammatory bowel disease, has been extensively studied in both animal models and human subjects. However, it has become increasingly clear that the intestinal microbiota plays important roles in the health of sites distant to the intestine including the skin, lungs, arteries, and bone.

Bone is an organ that the gut has long been known to regulate through absorption of the key bone mineral, calcium. An increasing number of studies suggest that there are additional ways to regulate bone health, including the microbiome. A number of research groups have studied the role of the microbiome and its effects on bone using a variety of approaches focusing on (1) direct alterations of the microbiota, (2) treatment with prebiotics to select for growth of certain bacteria in the gastrointestinal (GI) tract, and (3) treatment with probiotics to directly deliver beneficial bacteria to the GI tract. Here, we review these studies, focusing on how the gut environment can affect bone health (see Fig. 1).
The gastrointestinal tract can be considered a tube of the “outside” running through the body that allows the organism to sample the environment and take in nutrients. In addition to food, the “outside” includes foreign cells and particles, such as bacteria, viruses, and fungi, which enter the body and can take up occupancy in the gut microbiome. The intestinal microbiota plays multiple, essential roles in human and animal health and has thus been referred to as a forgotten organ [1, 2]. The microbiome of the gut, defined as the collective genetic material of the microbiota, contains an estimated 3–8 million unique genes, which expands the genetic capacity of humans by >100-fold [3, 4]. Although most work has focused on the colonic microbiota, all sections of the intestine are colonized with microbes with increasing density moving from the duo-"10—13" 12—15 bacteria per gram of feces; it is clear we have many more bacteria populating our intestinal tract than we have cells in our body. Some of the activities provided by these communities include maturation and regulation of the immune system, digestion and release of essential dietary nutrients, support of intestinal barrier function, and the ability to suppress pathogen invasion. Moreover, microbes contribute to the production of an estimated 10–35% of metabolites detected in urine and feces [5, 6]. This further underscores the major impact of the microbiota in animal and human health.

Until recently, the role of the microbiota and therapeutic bacteria in bone physiology and health was largely ignored. Few studies have directly tested how bacterial populations impact bone, although some common themes have been proposed. Three main areas in which the microbiota is being investigated for its impact on bone are nutrient acquisition (calcium and phosphate), immune regulation, and direct effects through production of small molecules such as serotonin or estrogen-like molecules. While there are a few reports of individual bacteria (usually probiotics) impacting multiple aspects of bone physiology, we are far from understanding the complex interplay between the intestinal microbiota and bone health.

While studies demonstrating that probiotics and prebiotics can impact bone health have been published, the most direct evidence that the intestinal microbiota interacts with the host to modulate bone density came from a study comparing germ-free mice with animals that were conventionally housed under conditions promoting a typical intestinal community (denoted conventionally raised or CONV-R) [7•]. Germ-free mice had a 50% increase in their femur trabecular bone volume fraction and increased cortical bone when compared to CONV-R animals. Histomorphometry demonstrated that CONV-R animals had increased osteoclast numbers per area of bone compared to germ-free animals [7•], suggesting increased bone catabolic activity in the presence of intestinal microbiota.

Previous work has demonstrated that inflammation in the bone marrow contributes to bone loss due to gut inflammation [8] and ovariectomy (OVX) [9, 10]. It has been hypothesized that increased levels of activated T cells lead to enhanced expression of TNFα in the bone marrow. TNFα stimulates osteoclastogenesis, disrupting the normal balance of bone formation and resorption [11, 12]. Although the mechanism by which activated T cells are increased in the bone marrow is not understood, a likely culprit for T-cell activation could be antigens presented by the intestinal microbiota [10]. Consistent with the role of T cells in bone physiology, CONV-R animals display increased levels of CD4+ T cells, TNFα, and osteoclast precursor cells (CD4+/GR1−) compared to germ-free animals [7•]. Importantly, transferring a microbial community to germ-free female mice at 3 weeks of age led to decreased
bone density, increased bone marrow CD4+ T cells, and increased osteoclast precursors [7•], demonstrating a critical role for the microbiota in mediating bone physiology. While this study indicates an impact of intestinal microbes in bone physiology, other interesting questions were raised. First, these experiments were only performed in female animals; whether or not male mice would be similarly impacted is not known. Second, CONV-R mice had a higher mineral apposition rate than germ-free mice, suggesting that bone formation may be increased by gut microbiota in addition to increased osteoclast numbers. Third, phenotypic analysis of the bone was not performed (e.g., bone-strength measurements) so that while germ-free animals have a higher bone density, other parameters may be abnormal in the absence of microbes.

Additional support for microbial regulation of bone health comes from three studies from Martin Blaser’s group investigating the impact of antibiotics on bone during early mouse development. Brief exposure of weaning mice to subtherapeutic concentrations of penicillin, vancomycin, or chlorotetacycline resulted in a significant increase in bone mineral density after 3 weeks, although at 7 weeks the control mice had caught up to and were similar to antibiotic-treated animals [13]. A similar impact on bone mineral density was also observed in a mouse model aimed at recreating therapeutic pediatric antibiotic exposure typically observed in children [14]. Animals treated with tylosin, amoxicillin, or a mixture of both had larger bones and higher bone mineral content than controls. Interestingly, if animals were exposed to low levels of penicillin from birth, it was found that sex-specific effects on bone occurred [14]. Male mice exposed to penicillin at weaning showed reduced bone mineral content and bone area compared to controls, and this loss was further exacerbated by the introduction of penicillin at birth. Female mice surprisingly showed improved bone mineral content and bone mineral density when exposed to penicillin (delivery of penicillin at weaning or birth made no difference). This study shows that antibiotics can have sex-specific impacts on bone health. However, because these studies were longitudinal, the bones were analyzed by dual energy X-ray absorptiometry (DEXA), and therefore, high-resolution analysis of trabecular and cortical bone was not performed. Nonetheless, these results are consistent with an altered intestinal microbiota.

**Prebiotic Effects on Bone**

Intestinal dysbiosis, defined as a shift in the microbial ecology of the gut to an unhealthy state, is linked with diseases and bone loss. While we are beginning to understand the changes in microbial composition associated with dysbiosis, the functional changes are far less understood. Bacteria express a variety of genes that can be modulated in response to changes in the environment. Many of these genes encode for enzymes involved in the production of metabolites such as short-chain fatty acids (SCFA, i.e., butyrate), branch-chained fatty acids, bile acid derivatives, and vitamins. The generation of metabolic products by bacterial action is dependent on the substrate availability. These substrates are in part provided by prebiotics, and therefore, prebiotics are critical components that can be used to modify the type of metabolites produced by the intestinal microbiota. Prebiotics are non-digestible (by humans) fermentable food ingredients that promote the growth of beneficial microorganisms in the intestine as well as promote health-benefiting changes in microbiome activity (i.e., metabolites) [15]. What constitutes a prebiotic is under debate, and the definition may be expanded “metabolizable food ingredients” (instead of fermentable food ingredients) to incorporate a variety of bacteria-metabolized substrates besides carbohydrates, such as phenolic compounds [16]. It is also possible that prebiotics could have direct immunologic or anti-pathogen effects on their own without metabolite production [16]. Prebiotics encompass compounds found in a variety of foods such as chicory, garlic, leek, Jerusalem artichoke, dandelion greens, banana, onion, and bran that are readily available in grocery and health-food stores. In many cases, a significant amount of the food is needed to get enough prebiotic for activity; therefore, prebiotics, such as inulin, have been developed into soft-chew, capsule, tablet, or shake forms and are manufactured by a variety of companies. Prebiotics include a large group of non-digestible oligosaccharides (NDOs) that contain typically 2–10 sugar subunits but can have greater than 60 subunits [17]. NDOs include a variety of structures: polydextrose, fructo-oligosaccharides (FOS, the first defined prebiotic in 1995), inulin (which contains FOS and is often extracted from chicory root), xyllo-oligosaccharides (from xylan), galacto-oligosaccharides (GOS, produced from lactose), and soybean oligosaccharides (extracted from soybean whey). The microbiota can effectively breakdown most ingested prebiotics resulting in virtually no prebiotics in the stool [17]. Prebiotics appear to be safe when given to healthy children and adults and do not have major side effects except that they can cause bloating, gas, and increased bowel movements. In fact, the Food and Agriculture Organization of the United Nations World Health Organization supports the addition of prebiotics to infant (>5 months) formulas [18].

Over the past 20 years, many studies have identified a beneficial role of prebiotics in mineral metabolism, specifically enhancement of calcium absorption in both rodents and humans [17, 19]. For example, enhanced calcium absorption has been observed in healthy male rats treated with GOS or inulin [20, 21], healthy female rats treated with polydextrose for 4 weeks [22], and healthy female mice treated for 6 weeks with agave fructose and inulin [23]. Benefits can also be observed under pathologic conditions. For example, gastrectomized male rats treated with either FOS or difructose anhydride III (DFAIII, a non-digestible disaccharide)
displayed increased calcium absorption [24, 25]. Estrogen deficiency is known to reduce calcium absorption, and thus, the role of prebiotics on ovariectomized rodents has been significantly studied. Both inulin and FOS increased calcium absorption in estrogen-deficient ovariectomized (OVX) rats as determined by $^{45}$Ca tracer measurements [26]. Similarly, DFAIII (15 g/kg diet for 4 weeks) increased calcium absorption in OVX rats fed a normal diet and remarkably in vitamin-D-deficient control and OVX rats [27]. In humans, prebiotics such as FOS increase calcium absorption in adolescent boys and girls in a range of treatment times from 9 days [28], 3 weeks [29], to 1 year [30]. In a double-blind, placebo-controlled cross-over study, 6 weeks of treatment with FOS increased calcium and magnesium absorption in postmenopausal women (average age 72 years old±6.4 years) [31]. While not all subjects responded to treatment, the ones with pausal women (average age 61) demonstrated that 24 months of short-chained FOS treatment reduced serum and urine bone turnover markers [42].

A key question is the following: does the increase in calcium absorption observed with prebiotic treatment translate into increased bone health, i.e., increased bone density and improved architecture? Under healthy control conditions, FOS and inulin increase trabecular and cortical thickness and bone calcium levels in mice [23] and increase bone mineral content, femoral bone volume, and density in male rats [21, 33]. While there are variations in the effects of fibers, a study testing the role of eight different prebiotic fibers in weanling rats demonstrated that most (including soluble corn fiber, soluble fiber dextrin, polydextrose, and inulin/FOS) had significant effects on bone density measures, with all trending to or significantly increasing cortical thickness, cortical bone mineral content, and trabecular bone mineral density [34]. Under estrogen-deficient conditions, GOS, FOS, and isolavones prevented bone loss in OVX rats and mice [35, 36]. In gastrectomized rats, FOS prevented osteopenia [37]. It should be noted that many prebiotic studies did not measure bone density, and among those that did, several did not observe an effect [22, 38]. In addition to studies in rodents, prebiotics have been studied in other animals including chickens and pigs. In broiler chickens, inulin treatment increased bone mineralization/calcium content [39], while in pigs, inulin did not impact bone health [40]. In humans, the effects of inulin on peak bone mass acquisition, menopausal bone loss, and senile osteoporosis have been reviewed. [41] As expected, short studies do not show changes in bone density, but a 1-year FOS-treatment study was long enough to detect an increase in whole-body bone mineral density in adolescent girls [30]. Similarly, 1 year of FOS treatment reduced bone loss in postmenopausal women [42].

In addition to changes in bone architecture and mineralization, measures of actual bone strength are important. Prebiotics, such as FOS, increased bone strength in several rodent studies including in OVX models [43]. Similarly, GOS dose dependently increased rat tibia and femur strength [44, 45]. In addition, Anoectochilus formosanus, a prebiotic herb, and inulin also increase bone strength in 12-week-old OVX rats [46]. This effect on bone strength was observed in the absence of a significant change in bone volume, suggesting that prebiotics could change the extracellular matrix material properties.

Regarding effects of prebiotics on bone turnover, several studies indicate that prebiotics can affect osteoblast and/or osteoclast activity, with the response likely dependent upon the condition and prebiotic used. Some studies indicate bone formation is increased. For example, agave fructans and inulin increase serum osteocalcin levels in female mice 6 weeks after treatment [23]. A GOS/FOS combination given with calcium increased bone mineralization and density and, more importantly, enhanced osteoblast surface [47]. In contrast, inulin and FOS decreased the bone resorption-to-formation ratio in OVX rats [26]. Similarly, 4 weeks of FOS or DFAIII decreased resorption markers in gastrectomized rats [25]. Consistent with the latter rodent studies, a randomized intervention study in postmenopausal women (average age 61) demonstrated that 24 months of short-chained FOS treatment reduced serum and urine bone turnover markers [42].

Studies examining optimal prebiotic treatments for bone health have combined prebiotics with other bone-benefiting compounds/activities. For example, FOS treatment (for 70 days) maximizes the effect of soy isoflavone treatment on BMD in OVX rats, making the lowest isoflavone dose of 10 μg/g/day effective. The combination also enhanced effects on bone strength at doses of 20 μg/g/day and above. This effect appeared to result from a decrease in bone resorption rather than increased bone formation [43]. Another study examined the effect of exercise with DFAIII treatment on bone health. The combination resulted in even greater increases in femoral calcium content, strength, and total BMD [48]. Taken together, some prebiotics are more effective than others, and some combinations of prebiotics and/or functional foods display even greater effects than when given alone. Variations between studies may result from differences in dose, age, treatment length, and/or rodent model strain and background and gender.

While many studies demonstrate prebiotics can benefit bone health, the exact mechanisms are not fully clear [38, 41, 49]. Prebiotic enhancement of calcium absorption is at the heart of the majority of mechanisms, as this would supply mineral for bone formation. Models for how prebiotics could increase calcium absorption include the involvement of fermentation of the prebiotics to release SCFA. It has been demonstrated that many prebiotic fibers (i.e., soluble corn fiber or fiber dextrin, inulin, FOS, agave fructans) increase the cecal content of SCFA such as acetate, propionate, butyrate, isobutyrate, valerate, and isovalerate [23, 34, 46]. SCFA can
affect calcium absorption via two mechanisms. First, SCFA can directly affect the epithelium to enhance calcium absorption. This can be measured as an increase in cecum weight and/or histologically by increased cecal villi structures that maximize surface area and absorption [50]. There could also be increased paracelllular fluid transport under these conditions and increased calcium-binding protein expression [46, 50]. Secondly, production of SCFA increases acidity in the lumen of the cecum and colon. This is thought to occur by direct acidification by SCFA as well as by SCFA (butyrate) activation of H/Ca exchange. The lowered pH helps enhance mineral solubility making calcium more absorbable [50]. For example, like most prebiotics, the GOS dose dependently decreases cecal pH and increases cecal wall weight in rats [44, 45]. It should be noted, however, that there is no correlation between cecal SCFA levels and bone benefits [34]. It is possible that SCFA levels in other regions of the gut, such as the proximal or distal colon, may better correlate with bone benefits. Thus, the site of prebiotic effects/metabolites could also play a role in bone effectiveness. While a variety of SCFA are released in the cecum, studies show the potential for a different SCFA fingerprint in the colon. For example, treatment with agave fructans or inulin increases the levels of a variety of SCFA in the cecum but only acetate, propionate, and butyrate levels in the colon [23]. Similarly, DFAIII being shorter than FOS is thought to be more readily fermented in the proximal rather than distal colon whereas more complex long-chain prebiotics take longer to digest and can still be detected in the distal large intestine [48].

Prebiotics can also alter the microbiome composition, which could affect SCFA production and alter bone health. Compounds such as FOS and GOS are known to increase the proportion of bifidobacteria in the gastrointestinal tract [44, 45]. Inulin and FOS have been demonstrated to change bacterial species numbers in both the proximal and distal gut, significantly increasing bifidobacteria, lactobacilli (proximal gut only), and eubacteria while decreasing clostridia in the distal gut [51]. It is thought that stimulation of bifidobacteria levels leads to their increasing cleavage of isoflavone conjugates to yield their metabolites thereby increasing bioavailability of phytoestrogens (i.e., daidzein). A direct link between prebiotic-induced changes in the gut microbiome and enhancement of bone density has yet to be found but is an area of active research.

Probiotic Effects on Bone

The word “probiotics” was initially coined as an antonym for “antibiotics.” Bacterial species now recognized as probiotics have been used since ancient times for use in cheese and for fermentation of products. Over the years, the definition of probiotics has been refined and is now defined as “live microorganisms that when administered in appropriate amounts can provide certain health benefits to the host” [52]. Bacteria of the genera Lactobacillus, Bifidobacterium, Escherichia, Enterococcus, and Bacillus have been used for their probiotic effects. In addition, yeast (Saccharomyces) has been used as a probiotic. Generally, probiotics are provided as concentrated cultures in dairy products (e.g., yoghurt) or as inoculants in milk-based food or as dietary supplements in the form of powder, capsules, or tablets. More recently, they have been added to non-conventional products such as toothpaste, ice cream, and beer. How probiotics impact healthy and diseased animals and humans is an area of intense research and interest to the general public. Given that probiotics are readily available in grocery stores in the form of yoghurt and other food items that are part of everyday food intake, probiotics are being tested in various conditions, including bone health.

Some of the early studies examining the effectiveness of probiotics on bone health came from the poultry industry. Probiotics have been used in poultry for their beneficial effects on egg-shell quality and egg-laying performance. For example, Abdelgader et al. have shown that Bacillus subtilis feeding improves egg performance and egg-shell quality in hens [53]. In addition, probiotics have been studied in broiler chickens for improving performance and bone health. In one study, broiler chickens fed a low non-phytate phosphate diet were supplemented with active Mitsukella jalaludinin culture broth, which resulted in better performance in terms of nutrient availability and a significant increase in tibial mineral ash [54]. In addition, probiotic supplementation (Bacillus licheniformis and B. subtilis) of broilers significantly increased the tibial thickness of the lateral and medial walls and the tibiotarsal index. [55] Another study tested the effect of B. subtilis on the ash and calcium content of the tibia in chicks in the presence and absence of Salmonella enteritidis infection [56]. In this study, the age of the chicks was found to be an important factor in influencing the positive effects of the probiotic or the negative effects of infection, with effects being more prominent in the young chicks. Thus, overall, probiotics appear to have beneficial effects on the growth and performance of hens and broiler chickens.

In addition to their practical application in the poultry industry, probiotics have also been tested either as a treatment or adjuvant therapy to prevent periodontitis-induced bone loss. Oral administration of B. subtilis reduced rat alveolar bone loss induced by ligature-induced periodontitis and also protected rats from small intestinal changes induced by periodontal inflammation [57]. Stress was identified to influence the extent of the effect of probiotic therapy in periodontitis models [58], such that the effects of the probiotic (B. subtilis) are less effective in the presence of stress. In another periodontal study, oral Saccharomyces cerevisiae was used as a monotherapy or combined as an adjuvant with standard therapy and in both cases led to effective repair processes including less alveolar bone loss, decreased pro-
inflammatory cytokines TNFα and IL1β, and increased anti-inflammatory cytokine IL-10 [59]. Topical application of Lactobacillus brevis CD2, by placing a lyophilized patch between the gingiva and buccal mucosa of the tooth ligated for induction of periodontitis, significantly prevented ligature-induced periodontal bone loss [60]. In this study, expression levels of several pro-inflammatory mediator genes were markedly decreased in the probiotic-treated group, and evidence was provided to support that the anti-inflammatory effect was likely mediated through arginine deiminase, which is produced by the probiotic bacteria. Another study using rats examined the effect of broccoli supplementation on high-cholesterol-diet-induced systemic and alveolar bone changes especially in the periodontal tissue [61]. Importantly, they also included fermented broccoli, in which the broccoli was fermented with Bifidobacterium longum. The high-cholesterol diet induced a significant increase in the number of TRAP-positive osteoclasts, but this was prevented in the broccoli-supplemented group (both unfermented and fermented). The fermented group, however, had a greater decrease in the TRAP-positive osteoclasts suggesting that the B. longum-mediated fermentation is able to induce a beneficial effect compared to unfermented broccoli. The effect of unfermented and fermented broccoli was linked to high serum antioxidant levels induced by the broccoli supplementation.

In one of the earlier studies looking at the role of probiotics in bone health in healthy mice, it was hypothesized that the anti-TNFα activity of Lactobacillus reuteri ATCC PTA 6475 could help suppress TNF-mediated bone resorption. Interestingly, L. reuteri treatment was indeed able to improve bone health in healthy mice. This, however, was selective in terms of gender: L. reuteri increased bone volume fraction, bone mineral density, and bone mineral content only in the male mice but not the females [62]. Effects in the male mice were not specific for a particular bone site; both femoral and vertebral bones showed increased bone density. Even though other studies have found gender-specific responses in different conditions, the specific effect of L. reuteri on bone parameters and its gender dependence was intriguing. Correspondingly, in the absence of estrogen (and possibly progesterone), L. reuteri treatment was able to increase bone density in female OVX mice, demonstrating the role of sex hormones in shaping the response to the probiotic [63]. These effects of probiotics on bone were also reproduced by another group [64], demonstrating that L. reuteri is a critical regulator of bone health under estrogen-depleted conditions. Similar attenuation of bone loss was also observed with soy skim milk supplemented with Lactobacillus paracasei subsp. paracasei NTU101 or Lactobacillus plantarum NTU 102 in OVX mice [65]. Narva et al, have also shown similar results using milk fermented with Lactobacillus helveticus LBK-16H in a rat OVX model. However, it should be noted that some of the bone parameters did not completely return to sham levels in the probiotic-fermented milk-treated group [66]. As discussed by the authors in this study, the fermented milk used in the above two studies could lead to an increase in calcium absorption thereby enhancing bone health in the OVX rat model. However, work on L. reuteri in the OVX mouse model suggests that even in the absence of milk, probiotics are able to benefit bone health under low-estrogen or estrogen-depleted conditions.

In addition to the benefits of probiotics in promoting bone health under estrogen-depleted conditions, Zhang et al. [67] recently demonstrated that L. reuteri can reverse type 1 diabetes (T1D)-mediated bone loss and marrow adiposity in mice. Further analyses indicated that L. reuteri prevents diabetes and TNFα suppression of Wnt10b RNA levels in whole bone and osteoblasts in vitro, respectively [67]. This is an intriguing finding because previous studies in menopause rodent models, where osteoclast activity is increased, suggested that L. reuteri can suppress osteoclast activity [63]. Whereas, in the T1D model, bone loss is predominantly due to osteoblast dysfunction, yet L. reuteri is able to stimulate osteoblast activity under these conditions. These results suggest that L. reuteri is able to affect multiple mechanisms of bone remodeling under different pathophysiological conditions. Interestingly, probiotics have been found to be of benefit to bone health in spontaneously hypertensive rats. This condition promotes bone loss, but supplementation of milk fermented with L. helveticus significantly increases bone mineral density and bone mineral content compared to water or skim milk or sour-milk-treated rat groups [68]. Although further mechanisms were not addressed, these results underscore the possible utility of probiotics in a wide range of “bone loss” pathologies.

Studies have also tried to examine if a combination of probiotics with prebiotics, also known as symbiotics, can benefit bone health better than one or the other. For example, a probiotic (B. longum) given with or without yacon flour (a prebiotic) enhanced bone mineral content in rats, though strength was not significantly affected [69]. Importantly, the effect of the prebiotic was markedly increased by the probiotic. However, it should be noted that the probiotic by itself provided significant benefit to bone mineral content even without the prebiotic.

Probiotics, by virtue of being microorganisms, have been studied for their effects in immune-modulated conditions. In this regard, they have generally been found to be of benefit in hyperinflammatory conditions. Enterococcus faecium is a probiotic that is similar to other lactic acid bacteria in that it can transiently colonize the intestine in humans and provide beneficial effects. One study examined this probiotic in a rat adjuvant-induced arthritis model (treated with methotrexate) which evokes a significant whole-body decrease in bone mineral density [70]. Interestingly, even though the probiotic by itself was not beneficial in the pathogenesis, in the presence of methotrexate, E. faecium treatment provided significant
potentiation of the beneficial effect of the methotrexate treatment. Moreover, it also prevented whole-body bone mineral density loss in the arthritic rats. Similar anti-inflammatory effects equivalent to indomethacin treatment (non-selective cyclooxygenase inhibitor, a non-steroidal anti-inflammatory drug) have also been shown in collagen-induced arthritis (CIA) model in rats treated with Lactobacillus casei. Interestingly, while indomethacin suppressed all cytokines (pro and anti) broadly, L. casei inhibited pro-inflammatory cytokines TNFα and IL-6 and enhanced anti-inflammatory cytokine IL-10 [71••]. Probiotics also could be useful in conditions where there is a compromised immune system. For example, malnutrition in mice alters B-cell development in bone marrow, and treatment of these mice with Lactobacillus rhamnosus CRL 1505 reverses the negative effects of malnutrition thereby rendering the immune system to better fight against infection [72]. In addition, under conditions of acute graft-versus-host disease model, oral administration of L. rhamnosus GG before and after transplantation resulted in reduced disease as well as improved survival [73]. Although further studies are obviously necessary to determine if probiotics are safe in immunocompromised patients, it is possible that probiotics are safe in a broad cohort of healthy and patient populations.

In addition to rodent models and poultry, effects of probiotics on bone health have also been tested in zebrafish models. Interestingly, addition of L. rhamnosus to normal zebrafish microflora leads to faster backbone calcification [74]. This was associated with stimulation of the insulin-like growth factor (IGF) system by L. rhamnosus. It would be interesting to test if these effects on the IGF system are also observed in rodent and humans. In different studies, L. rhamnosus was shown to regulate genes involved in osteocyte formation via MAPK1/3 pathway in zebrafish providing additional molecular mechanism [75].

Conclusions

There are many studies supporting a role for the gut and its microbiome in the regulation of bone density and health. Direct modulation of the quantity of bacteria present (through the use of antibiotics, germ-free mice) as well as addition of bacterial substrates (prebiotics) and addition of beneficial bacteria (probiotics) can affect measures of bone health and calcium metabolism. However, there is still much to learn regarding our understanding of the signaling pathways that link the microbiome and gut to skeletal health. Future studies should be directed at identification of the mechanisms by which the microbiome regulates osteoblast and osteoclast activities as a means for developing future natural treatments for osteoporosis. We envision that modulation of the intestine-microbiome interaction to improve bone health will play an important role in human health and allow physicians to reduce the dependence on current pharmacological interventions for osteoporosis (which can have unwanted side effects).

Acknowledgments The authors would like to acknowledge funding from NIH: NCCIH R01AT007695 and NIDDK R01DK101050.

Compliance with Ethics Guidelines

Conflict of Interest Dr. McCabe reports grants from BioGaia, during the conduct of the study; in addition, Dr. McCabe has a patent on the selection and use of lactic acid bacteria for bone health (United States Patent Application 20150150917 issued).

Dr. Britton reports grants from BioGaia, during the conduct of the study. In addition, Dr. Britton has a patent on the selection and use of lactic acid bacteria for bone health (United States Patent Application 20150150917).

Dr. Parameswaran has nothing to disclose.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major importance


